CR7 becomes ‘significant shareholder’ in Bioniq, a provider of personalized supplements based on blood biomarker data and AI.
Global soccer superstar Cristiano Ronaldo has taken playing for extra time to a new level by making a “significant investment” in British consumer health company Bioniq. The company offers personalized supplements created using a combination of blood biomarker data and an AI-driven algorithm, to promote healthspan and longevity.
According to Bioniq, Ronaldo, a user of the London-based company’s supplements since 2022, will not only hold a stake in the company but will also contribute to product innovation. Known for his dedication to maintaining his health and performance over a stellar career, Ronaldo’s strategic involvement aims to tap into insights from his experience as an elite athlete to help shape the company’s future direction.
“Backing Bioniq goes beyond just an investment opportunity for me – it’s about aligning with a shared vision for health, performance, and longevity,” said Ronaldo in a statement. “I have been using their products myself for almost three years. With their personalized health approach, I believe Bioniq has the potential to transform how we care for our bodies and help people reach and maintain their peak performance for longer.”
Bioniq’s personalized model rejects the idea of a one-size-fits-all approach to supplementation, instead using data to tailor nutrient support for each user. Leveraging a proprietary biochemical database based on blood test data from users around the world, the company creates completely unique supplements designed to help users optimize their nutrient levels.
The company’s AI-powered platform analyzes various factors, such as age, lifestyle, and health goals, to determine the ideal micronutrient mix for each person. Its patented micro-dosing technique ensures that every user’s supplement is custom-made, delivering up to 120 different nutrients in prebiotic granules designed to maximize absorption and minimize nutrient competition in the body.
When we interviewed Bioniq founder Vadim Fedotov earlier this year, he stressed that the company was founded with longevity at its heart.
“We’re supporting people’s path to optimize themselves, which will allow their body to perform better at a later point in their lifespan, and which I believe will lead to anti-aging,” he told us.
Through partnerships with major organizations, including Lanserhof and UFC, Bioniq has been accelerating its global expansion, particularly in the US, with over 60% of its global sales now coming from the US alone. With a core user base composed of athletes and individuals focused on longevity and performance, the company claims its customer base has expanded fivefold in 2024, and its supplements are now sold in over 70 countries.
Pushing Bioniq’s total valuation to $82 million, Ronaldo’s undisclosed investment follows a recent $15 million Series B funding round, led by HV Capital and Unbound.
“Cristiano using Bioniq to enhance his performance shows that our product delivers real results,” said David Kuczek, General Partner at HV Capital. “If it works for an elite athlete of his caliber, it’s clear that it can benefit ambitious consumers, helping them reach their own health and performance goals.”
